Article

Dellann Elliott Mydland on Testing Brain Tumor Tissue

Author(s):

Dellann Elliott Mydland

Dellann Elliott Mydland, from the Chris Elliott Fund, discusses testing brain tumor tissue before surgery.

Dellann Elliott Mydland, from the Chris Elliott Fund, discusses testing brain tumor tissue before surgery.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Dr. Doug
Expert Shares Key Insights During Melanoma Awareness Month
Image of doctor.
Understanding AYA Lymphoma Care and Why Treatment May Differ by Age
Image of Dr. Kelly
Breaking Down Barriers to Diagnosis in AYA Patients With Lymphoma
Image of Dr. Boffa.
How Cancer Care Teams Can Help With the Cessation of Smoking
Immune Therapy Expands Melanoma Treatment to More Patients
Immune Therapy Expands Melanoma Treatment to More Patients
Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan.
A Personalized Approach to Bladder Preservation in Urologic Cancers
image of doctor D'Sa
Mitigating Peripheral Neuropathy During Cancer Treatment
Image of Dr. Eng.
Dr. Eng Breaks Down Braftovi Plus Erbitux FDA Approval in BRAF+ mCRC
Image of Dr. Tagawa.
Breaking Down the Benefits of Clinical Trial Participation in Cancer Care
Most patients in accredited hospitals had smoking discussions documented, showing key care opportunities and smoking’s impact on treatment outcomes.
Smoking Data May Guide Improved Lung Cancer Care and Patient Support
Related Content
Danyelza is now a recommended treatment in NCCN guidelines for high-risk neuroblastoma: © sudok1 - stock.adobe.com.
May 8th 2025

Danyelza Added to NCCN Guidelines for High-Risk Neuroblastoma

Spencer Feldman
Danyelza is now a recommended treatment in NCCN guidelines for relapsed or refractory high-risk neuroblastoma, a type of brain cancer.
Site Logo
August 29th 2019

Earning Your Legacy: Cancer Has Nothing To Do With It

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Matt Newman, who was diagnosed with brain cancer at 39, but refuses to let cancer define the legacy he has made.
An AI model using serial brain scans predicted glioma recurrence in children with up to 89% accuracy: © LukaszDesign - stock.adobe.com
May 5th 2025

AI Tool Predicts Pediatric Glioma Recurrence With Up to 89% Accuracy

Spencer Feldman
An AI model using serial brain scans predicted glioma recurrence in children with up to 89% accuracy, outperforming single-image methods.
Site Logo
April 11th 2019

Addressing Nutritional Needs in Cancer

Kristie L. Kahl
In this week’s episode, we spoke with the founder and CEO of Savor Health on the importance of nutrition for patients and caregivers before, during and after cancer treatment.
FDA sign.
April 23rd 2025

FDA Grants Breakthrough Status to CAR-T Therapy for Pediatric Brain Tumor

Ryan Scott
The FDA granted breakthrough therapy designation to an autologous CAR-T cell therapy for pediatric patients with diffuse intrinsic pontine glioma.
People can help EBCI reach their goal of $20,000 dollars raised for GiveBIG 2025 by giving at endbraincancer.org/donate: © stock.adobe.com.
April 22nd 2025

Support Patient Access and Education with the End Brain Cancer Initiative for GiveBIG 2025

End Brain Cancer
People can help EBCI reach their goal of $20,000 dollars raised for GiveBIG 2025 by giving at endbraincancer.org/donate.